aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
aTyr Pharma (LIFE) PT Lowered to $1 at BMO Capital
August 15, 2018 7:29 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $1.00 (from $2.00) while maintaining a Market Perform rating.
... MoreaTyr Pharma (LIFE) Misses Q2 EPS by 2c
August 14, 2018 4:23 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33).
We have made important advancements in the development of our lead product candidate, ATYR1923, during the recent months, said Sanjay Shukla, M.D., M.S., President and CEO of aTyr.... More
